(NASDAQ: WHWK) Whitehawk Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.23%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.19%.
Whitehawk Therapeutics's earnings in 2026 is -$79,831,000.On average, 10 Wall Street analysts forecast WHWK's earnings for 2026 to be -$52,972,772, with the lowest WHWK earnings forecast at -$57,544,895, and the highest WHWK earnings forecast at -$50,880,541. On average, 9 Wall Street analysts forecast WHWK's earnings for 2027 to be -$49,540,830, with the lowest WHWK earnings forecast at -$59,220,960, and the highest WHWK earnings forecast at -$41,303,028.
In 2028, WHWK is forecast to generate -$43,543,482 in earnings, with the lowest earnings forecast at -$49,723,259 and the highest earnings forecast at -$29,331,136.